Seroprevalence and Predictors of Hepatitis B and C Virus Infections Among Patients with Chronic Liver Diseases in Dodoma Region, Tanzania: A Cross-Sectional Study.

IF 1.8 Q2 GASTROENTEROLOGY & HEPATOLOGY
Hepatic Medicine : Evidence and Research Pub Date : 2025-09-23 eCollection Date: 2025-01-01 DOI:10.2147/HMER.S533485
Daudi J Gyunda, James J Yahaya, Emmanuel M Sindato, Alfred J Meremo
{"title":"Seroprevalence and Predictors of Hepatitis B and C Virus Infections Among Patients with Chronic Liver Diseases in Dodoma Region, Tanzania: A Cross-Sectional Study.","authors":"Daudi J Gyunda, James J Yahaya, Emmanuel M Sindato, Alfred J Meremo","doi":"10.2147/HMER.S533485","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The known major causes of chronic liver diseases (CLDs) include, hepatitis B virus (HBV) and hepatitis C virus (HCV); however, there is scarcity of data regarding their seroprevalence in Tanzania. We aimed to evaluate the seroprevalence of HBsAg and anti-HCV and their predictors among patients with CLDs. Additionally, we also described the clinical patterns of the patients.</p><p><strong>Methods: </strong>A cross-sectional analytical study design was carried at the two referral public hospitals in Dodoma region; Dodoma referral regional hospital (DRRH) and Benjamin Mkapa hospital (BMH) among 118 patients with CLDs. Rapid test immunochromatography was used to test for HBsAg whereas anti-HCV antibody positivity was tested using lateral flow chromatographic immunoassay. Multivariable binary logistic regression was used to evaluate the predictors of HbsAg positive results, and statistical significance was set at p˂0.05.</p><p><strong>Results: </strong>The seroprevalence of HBsAg and anti-HCV antibody was 28% (33/118) and 3.4% (4/118), respectively. Having a chronic illness (AOR = 2.3, 95% CI = 1.76-7.19, p = 0.041), raised level of alanine transaminase (ALT) (AOR = 3.6, 95% CI = 1.74-8.21, p = 0.025), increased AST/ALT ratio (AOR = 2.9, 95% CI = 2.57-11.57, p = 0.039), and increased level of total bilirubin (AOR = 5.1, 95% CI = 1.09-24.39, p = 0.039) remained the predictors of HBsAg positivity.</p><p><strong>Conclusion: </strong>This study reports that almost one-third of the study subjects had positive HbsAg, and the positivity of anti-HCV antibody was quite low. The positivity of HbsAg was associated with having chronic illness, increased levels of ALT, total bilirubin, and AST/ALT ratio. Therefore, emphasis should be made to maximize the screening practices for individuals with such predictors due to high possibility of being infected with HBV.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":"17 ","pages":"125-140"},"PeriodicalIF":1.8000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476176/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Medicine : Evidence and Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/HMER.S533485","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The known major causes of chronic liver diseases (CLDs) include, hepatitis B virus (HBV) and hepatitis C virus (HCV); however, there is scarcity of data regarding their seroprevalence in Tanzania. We aimed to evaluate the seroprevalence of HBsAg and anti-HCV and their predictors among patients with CLDs. Additionally, we also described the clinical patterns of the patients.

Methods: A cross-sectional analytical study design was carried at the two referral public hospitals in Dodoma region; Dodoma referral regional hospital (DRRH) and Benjamin Mkapa hospital (BMH) among 118 patients with CLDs. Rapid test immunochromatography was used to test for HBsAg whereas anti-HCV antibody positivity was tested using lateral flow chromatographic immunoassay. Multivariable binary logistic regression was used to evaluate the predictors of HbsAg positive results, and statistical significance was set at p˂0.05.

Results: The seroprevalence of HBsAg and anti-HCV antibody was 28% (33/118) and 3.4% (4/118), respectively. Having a chronic illness (AOR = 2.3, 95% CI = 1.76-7.19, p = 0.041), raised level of alanine transaminase (ALT) (AOR = 3.6, 95% CI = 1.74-8.21, p = 0.025), increased AST/ALT ratio (AOR = 2.9, 95% CI = 2.57-11.57, p = 0.039), and increased level of total bilirubin (AOR = 5.1, 95% CI = 1.09-24.39, p = 0.039) remained the predictors of HBsAg positivity.

Conclusion: This study reports that almost one-third of the study subjects had positive HbsAg, and the positivity of anti-HCV antibody was quite low. The positivity of HbsAg was associated with having chronic illness, increased levels of ALT, total bilirubin, and AST/ALT ratio. Therefore, emphasis should be made to maximize the screening practices for individuals with such predictors due to high possibility of being infected with HBV.

坦桑尼亚Dodoma地区慢性肝病患者乙型和丙型肝炎病毒感染的血清阳性率和预测因素:一项横断面研究
背景:已知的慢性肝病(CLDs)的主要病因包括乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV);然而,坦桑尼亚缺乏关于其血清流行率的数据。我们的目的是评估乙肝表面抗原(HBsAg)和抗丙肝病毒(anti-HCV)的血清患病率及其在CLDs患者中的预测因子。此外,我们也描述了患者的临床模式。方法:采用横断面分析研究设计,对Dodoma地区两家转诊公立医院进行分析;118例CLDs患者在Dodoma转诊地区医院(DRRH)和Benjamin Mkapa医院(BMH)就诊。采用快速检测免疫层析法检测HBsAg,采用侧流层析免疫法检测抗hcv抗体阳性。采用多变量二元logistic回归评估HbsAg阳性结果的预测因子,p值小于0.05。结果:血清HBsAg和抗hcv抗体阳性率分别为28%(33/118)和3.4%(4/118)。慢性疾病(AOR = 2.3, 95% CI = 1.76 ~ 7.19, p = 0.041)、丙氨酸转氨酶(ALT)水平升高(AOR = 3.6, 95% CI = 1.74 ~ 8.21, p = 0.025)、AST/ALT比值升高(AOR = 2.9, 95% CI = 2.57 ~ 11.57, p = 0.039)、总胆红素水平升高(AOR = 5.1, 95% CI = 1.09 ~ 24.39, p = 0.039)仍是HBsAg阳性的预测因子。结论:本研究报告近三分之一的研究对象HbsAg阳性,抗hcv抗体阳性率较低。HbsAg阳性与慢性疾病、ALT、总胆红素和AST/ALT比值升高有关。因此,由于感染乙肝病毒的可能性高,应该强调对具有这些预测因子的个体进行最大限度的筛查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Hepatic Medicine : Evidence and Research
Hepatic Medicine : Evidence and Research GASTROENTEROLOGY & HEPATOLOGY-
自引率
0.00%
发文量
15
审稿时长
16 weeks
期刊介绍: Hepatic Medicine: Evidence and Research is an international, peer-reviewed, open access, online journal. Publishing original research, reports, editorials, reviews and commentaries on all aspects of adult and pediatric hepatology in the clinic and laboratory including the following topics: Pathology, pathophysiology of hepatic disease Investigation and treatment of hepatic disease Pharmacology of drugs used for the treatment of hepatic disease Although the main focus of the journal is to publish research and clinical results in humans; preclinical, animal and in vitro studies will be published where they will shed light on disease processes and potential new therapies. Issues of patient safety and quality of care will also be considered. As of 1st April 2019, Hepatic Medicine: Evidence and Research will no longer consider meta-analyses for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信